Want to see AU:VBS full AI Analyst Report?
VBS Stock Chart & Stats
AU$0.18
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.18
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.46
Previous CloseN/A
Volume32.26K
Average Volume (3M)97.35K
Market Cap
AU$12.34M
Enterprise ValueAU$8.15M
Total Cash (Recent Filing)AU$330.50K
Total Debt (Recent Filing)AU$467.10K
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding61,690,350
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA consistently very high gross margin profile indicates strong unit economics for Vectus Biosystems' core offerings. Durable gross margin advantages can support long-term operating leverage, allowing the company to absorb R&D and SG&A while improving path to profitability if revenue stabilizes and scales.
Modest Absolute DebtModest absolute debt reduces near-term interest burden and refinancing pressure, preserving financial optionality. For a clinical-stage biotech, lower nominal leverage supports flexibility to raise non-debt funding or pursue partnerships without immediate solvency stress, provided operational losses are controlled.
Improved Cash Burn In FY2025An improvement in cash burn year-over-year suggests management has begun to rebase spending or improved operational efficiency. Sustained reduction in cash outflows materially extends runway, reduces frequency of dilutive financings, and strengthens the company's ability to fund near-term development milestones.
Bears Say
Sharply Declining RevenueA 45.9% revenue decline is a durable red flag: it undermines scale economics and the company's ability to leverage its high gross margins. Persistently falling top-line revenue reduces forecast visibility, weakens negotiating leverage with partners, and makes reaching breakeven materially harder without new revenue sources.
Negative Shareholders' EquityNegative shareholders' equity reflects accumulated losses and erosion of the capital base, increasing funding and solvency risk. This structural weakness can restrict access to non-dilutive capital, raise covenant/default risks with lenders, and complicate long-term strategic options like partnerships or acquisitions.
Persistent Negative Cash GenerationConsistent negative operating and free cash flow means the business requires ongoing external funding to operate. Over the medium term this raises the probability of dilutive equity raises, asset sales, or cutbacks in development programs, undermining the firm's ability to execute on long-term clinical or commercial plans.
Vectus Biosystems Limited News
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.04 and its highest was AU$0.46 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$12.34M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Sep 02, 2026 which is in 47 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Feb 26, 2026. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 61,690,350 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vectus Biosystems Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.75%
12-Months-Change
Fundamentals
Return on Equity
265.12%
Trailing 12-Months
Asset Growth
-62.59%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Technical Analysis
Acrux
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―